The histone lysine methyltransferase NSD3 drives osteosarcomagenesis by inactivating ARID3A
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.218045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Jinchang Lu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, PR China; Princess Margaret Cancer Centr…. Hauptthemen laut MEDLINE: Histone-Lysine N-Methyltransferase, Osteosarcoma, Bone Neoplasms, Transcription Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Canadian Cancer Society, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Osteosarcomas (OS) have highly chaotic genomes, yet their cancer drivers are poorly defined. Leveraging cross-species OS genomics we identify the frequent amplification of NSD3, a histone lysine methyltransferase and expose the NSD3-ARID3A axis as a core pathway in osteosarcomagenesis. Loss- and gain-of-function studies with CRISPR-Cas9 and lentivirus systems establish the causal role of NSD3 in OS tumor growth and spontaneous metastasis. NSD3 specifically enhances H3K27 di-methylation to initiate oncogenic reprogramming and inactivates the transcriptional repressor ARID3A. This culminates in altered expression of instructive genes RUNX2, MMP13, OCT4 and NANOG generating a shift in osteosarcoma cell differentiation to a primitive state. In human OS, NSD3 overexpression is seen in patient tumors and predicts a poor clinical outcome. Our study uncovers the crucial epigenetic dysregulation of histone lysine methyltransferase in osteosarcoma, opening new possibilities for therapy with epigenetic drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, PR China; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 1L7, Canada; Depar…
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 1L7, Canada.
- Department of Orthopedic Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, PR China; Department of Musculoskeletal Oncology, State Key Laboratory of Oncology in South China, Guangdong P…
- Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, N1G 2W1, Canada.
- Department of Orthopedic Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, PR China. Electronic address: shenjn@mail.sysu.edu.cn.
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 1L7, Canada. Electronic address: rama.khokha@uhn.ca.
Förderung
- National Natural Science Foundation of China
- Canadian Cancer Society
- Canadian Institutes of Health Research
Zitieren
APA
Lu, J., Shao, Y., Saw, S., Fang, H., Song, G., Chen, Y., Tang, Q., Wood, G., Wang, J., Waterhouse, P., Shen, J., & Khokha, R. (2025). The histone lysine methyltransferase NSD3 drives osteosarcomagenesis by inactivating ARID3A. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218045
Vancouver
Lu J, Shao Y, Saw S, Fang H, Song G, Chen Y, et al. The histone lysine methyltransferase NSD3 drives osteosarcomagenesis by inactivating ARID3A. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.218045
BibTeX
@article{Lu2025,
author = {Lu, Jinchang and Shao, Yang and Saw, Sanjay and Fang, Hui and Song, Guohui and Chen, Yan and Tang, Qinglian and Wood, Geoffrey and Wang, Jin and Waterhouse, Paul and Shen, Jingnan and Khokha, Rama},
title = {The histone lysine methyltransferase NSD3 drives osteosarcomagenesis by inactivating ARID3A},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.218045}
}
EUVIMED